Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
Rhea-AI Summary
Disc Medicine (NASDAQ:IRON) announced two poster presentations at the 67th ASH Annual Meeting in Orlando on December 6-9, 2025, including initial data from the RALLY-MF Phase 2 trial of DISC-0974 in patients with myelofibrosis (MF) and anemia.
Presentations include DISC-0974 (Publication 2042) on Saturday, December 6 at 5:30–7:30pm EST (presenter Naseema Gangat) and DISC-3405 in polycythemia vera (Publication 2053) at the same session (presenter Marcus Carden). Management will host a data review call on December 7, 2025 at 7:30am EST. Abstracts are posted on the ASH site; new data reserved for conference presentation.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, IRON declined 1.77%, reflecting a mild negative market reaction. This price movement removed approximately $58M from the company's valuation, bringing the market cap to $3.21B at that time.
Data tracked by StockTitan Argus on the day of publication.
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced two poster presentations, including initial data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF, at the upcoming American Society of Hematology (ASH) Annual Meeting, which will be held in Orlando, FL on December 6-9, 2025.
“The highlight of our ASH presentations this year will be an initial look at data from RALLY-MF, our Phase 2 trial of DISC-0974 in anemia of myelofibrosis,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc Medicine. “Following the strong Phase 1b results we presented at ASH last year, we are eager to share an update on this program, including results from more patients from across the range of MF anemia patients, as a monotherapy and in combination with JAK inhibitor backbone therapies, including ruxolitinib and momelotinib. We will also present a poster on the design of our ongoing Phase 2 trial of DISC-3405 in polycythemia vera. We expect to share an initial readout for this trial, as well as for the Phase 1b trial of DISC-3405 in sickle cell disease, in 2026.”
Management will host a call during the ASH meeting to review highlights of the presented data and plans for next steps in development on Sunday, December 7 at 7:30am EST. Please register for the event on the Events and Presentations page of Disc’s website (https://ir.discmedicine.com/).
Details of Poster Presentations:
The abstracts are now available through the ASH conference website. Pursuant to Disc Medicine practice, the clinical study abstracts published today contain previously presented data; new data and analyses are reserved for presentation at the conference.
DISC-0974 Poster Presentation:
Publication Number: 2042
Title: RALLY MF: A phase 2 Study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia
Date / Time: Saturday, December 6, 5:30 pm – 7:30pm EST
Presenting Author: Naseema Gangat, M.B.B.S.
DISC-3405 Poster Presentation:
Publication Number: 2053
Title: A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)
Date / Time: Saturday, December 6, 5:30 pm – 7:30pm EST
Presenting Author: Marcus Carden, M.D., M.Sc.
About Disc Medicine
Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
Disc Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding: the projected timelines for the presentation of DISC-0974 data. The use of words such as, but not limited to, “believe,” “expect,” “estimate,” “project,” “intend,” “future,” “potential,” “continue,” “may,” “might,” “plan,” “will,” “should,” “seek,” “anticipate,” or “could” or the negative of these terms and other similar words or expressions that are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Disc’s current beliefs, expectations and assumptions regarding the future of Disc’s business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and investors should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of a number of material risks and uncertainties including but not limited to: the adequacy of Disc’s capital to support its future operations and its ability to successfully initiate and complete clinical trials; the nature, strategy and focus of Disc; the difficulty in predicting the time and cost of development of Disc’s product candidates; Disc’s plans to research, develop and commercialize its current and future product candidates; the timing of initiation of Disc’s planned preclinical studies and clinical trials; the timing of the availability of data from Disc’s clinical trials; Disc’s ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc’s preclinical studies and clinical trials and the risk that the results of Disc’s preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; and the other risks and uncertainties described in Disc’s filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Disc’s Annual Report on Form 10-K for the year ended December 31, 2024, and in subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law.
Media Contact
Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com
Investor Relations Contact
Christina Tartaglia
Precision AQ
Christina.tartaglia@precisionaq.com
FAQ
When will Disc Medicine (IRON) present initial RALLY-MF Phase 2 data at ASH 2025?
What time is the Disc Medicine (IRON) management call to review ASH data?
Which Disc Medicine programs are being presented at ASH 2025 and what are their focuses?
Who are the presenting authors for Disc Medicine posters at ASH 2025?
Where can investors find the Disc Medicine (IRON) ASH abstracts and register for the management call?
Will the RALLY-MF poster include new patient data not previously presented?
